PubRank

Hiroya Takiuchi

Author PubWeight™ 39.41‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 2011 5.39
2 Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009 5.19
3 Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 2010 2.73
4 Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys 2010 1.71
5 Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 2002 1.71
6 Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010 1.69
7 Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006 1.34
8 Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 2010 1.16
9 Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer 2011 1.08
10 Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma. Jpn J Clin Oncol 2007 1.08
11 Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. Oncology 2005 1.02
12 Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology 2008 0.98
13 A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 2009 0.93
14 A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 2006 0.93
15 Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002). Oncology 2008 0.92
16 A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer. Cancer Chemother Pharmacol 2008 0.92
17 Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study. Gastric Cancer 2012 0.92
18 Evaluation of prognostic factors of esophageal squamous cell carcinoma (stage II-III) after concurrent chemoradiotherapy using biopsy specimens. Jpn J Clin Oncol 2007 0.90
19 A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial). Gastric Cancer 2011 0.89
20 A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol 2010 0.88
21 Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. Jpn J Clin Oncol 2008 0.88
22 Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). Anticancer Res 2012 0.86
23 Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets. Jpn J Clin Oncol 2004 0.84
24 Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404). J Chemother 2013 0.81
25 A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer. Invest New Drugs 2011 0.81
26 [Case of disseminated carcinomatosis of bone marrow with severe alkalinephosphatasia, manifested 10 years after resection of early gastric cancer]. Nihon Shokakibyo Gakkai Zasshi 2004 0.80
27 Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial. Jpn J Clin Oncol 2007 0.79
28 Irinotecan is inactive as a first-line treatment, but plays an important part in gastric cancer treatment. Gastric Cancer 2011 0.79
29 [Combination of S-1 and paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis, feasibility study (OGSG0401)]. Gan To Kagaku Ryoho 2010 0.78
30 A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer. Jpn J Clin Oncol 2012 0.78
31 Adjuvant therapy in rectal cancer: what is the truth? Jpn J Clin Oncol 2006 0.77
32 [Weekly administration regimen of paclitaxel (PTX) in patient with inoperable or recurrent gastric cancer]. Gan To Kagaku Ryoho 2006 0.77
33 Gastric mucosal cell protection by epidermal growth factor in primary monolayer culture of guinea pig gastric mucous cells. J Gastroenterol 2003 0.77
34 A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for Advanced Stomach Cancer (TASC). Jpn J Clin Oncol 2007 0.75
35 [Serotonin syndrome in a patient with small cell lung cancer]. Gan To Kagaku Ryoho 2013 0.75
36 [A case of gastric cancer with multiple liver metastases resistant to TS-1 responding to chemotherapy with paclitaxel plus doxifluridine]. Gan To Kagaku Ryoho 2006 0.75
37 Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS. Jpn J Clin Oncol 2010 0.75
38 [A case of advanced gastric cancer with DIC treated by sequential MTX and 5-FU]. Gan To Kagaku Ryoho 2004 0.75
39 [A resected case of effective treatment with S-1+CPT-11 combination chemotherapy for advanced gastric cancer]. Gan To Kagaku Ryoho 2010 0.75
40 Evaluation of an electrolysis apparatus for inactivating antineoplastics in clinical wastewater. Chemosphere 2008 0.75
41 [The current status of adjuvant chemotherapy of colonic cancer]. Gan To Kagaku Ryoho 2009 0.75
42 [Lower G. I./colon and rectum cancer. IV. Standard chemotherapy of advanced, recurrent colonic cancer]. Gan To Kagaku Ryoho 2010 0.75
43 [Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)]. Gan To Kagaku Ryoho 2011 0.75
44 [Current status and perspectives of biologics in the treatment of metastatic colorectal cancer]. Nihon Rinsho 2010 0.75
45 [Comparison of chemotherapy side effects between elderly and young subjects]. Gan To Kagaku Ryoho 2012 0.75
46 [Effectiveness of chemotherapy for outpatients with gastric or colorectal cancer]. Gan To Kagaku Ryoho 2002 0.75
47 [S-1 combined with weekly paclitaxel in patients with advanced gastric cancer]. Gan To Kagaku Ryoho 2006 0.75
48 A problem-based learning tutorial for dental students regarding elderly residents in a nursing home in Japan. J Dent Educ 2012 0.75
49 [Chemotherapy for gastrointestinal cancer in elderly patients]. Gan To Kagaku Ryoho 2011 0.75
50 Phase I/II study of CPT-11 plus UFT in patients with advanced/recurrent colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102. Jpn J Clin Oncol 2007 0.75
51 Application of electrolysis for detoxification of an antineoplastic in urine. Ecotoxicol Environ Saf 2011 0.75
52 Metastatic malignant melanoma. Gastrointest Endosc 2002 0.75